Viracta Therapeutics Statistics
Total Valuation
VIRX has a market cap or net worth of $7.88 million. The enterprise value is $2.15 million.
Important Dates
The next estimated earnings date is Friday, November 15, 2024, before market open.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
VIRX has 39.42 million shares outstanding. The number of shares has increased by 2.06% in one year.
| Shares Outstanding | 39.42M |
| Shares Change (YoY) | +2.06% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 2.69% |
| Owned by Institutions (%) | 14.42% |
| Float | 24.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 7.05.
| Current Ratio | 1.08 |
| Quick Ratio | 1.05 |
| Debt / Equity | 7.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.32 |
Financial Efficiency
Return on equity (ROE) is -208.67% and return on invested capital (ROIC) is -70.45%.
| Return on Equity (ROE) | -208.67% |
| Return on Assets (ROA) | -57.20% |
| Return on Capital (ROIC) | -70.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.13M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.55% in the last 52 weeks. The beta is 0.30, so VIRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -71.55% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 0.58 |
| Relative Strength Index (RSI) | 33.31 |
| Average Volume (20 Days) | 1,743,088 |
Short Selling Information
The latest short interest is 1.10 million, so 2.80% of the outstanding shares have been sold short.
| Short Interest | 1.10M |
| Short Previous Month | 1.33M |
| Short % of Shares Out | 2.80% |
| Short % of Float | 4.45% |
| Short Ratio (days to cover) | 6.17 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -49.50M |
| Pretax Income | -47.99M |
| Net Income | -45.34M |
| EBITDA | -49.04M |
| EBIT | -49.50M |
| Earnings Per Share (EPS) | -$1.16 |
Full Income StatementBalance Sheet
The company has $30.01 million in cash and $18.82 million in debt, giving a net cash position of $11.19 million or $0.28 per share.
| Cash & Cash Equivalents | 30.01M |
| Total Debt | 18.82M |
| Net Cash | 11.19M |
| Net Cash Per Share | $0.28 |
| Equity (Book Value) | 2.67M |
| Book Value Per Share | -0.07 |
| Working Capital | 2.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.24 million and capital expenditures $51,000, giving a free cash flow of -$38.19 million.
| Operating Cash Flow | -38.24M |
| Capital Expenditures | 51,000 |
| Free Cash Flow | -38.19M |
| FCF Per Share | -$0.97 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |